Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Allergan Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (58)
Australian Public Assessment Report (AusPAR) (12)
Prescription medicine registration (2)
Prescription medicine decision summary (1)

Date

2023 (3)
2019 (18)
2018 (2)
2017 (26)
2016 (17)
2014 (1)
2013 (1)
2012 (1)
2011 (3)
2010 (1)

Results for "[search-keyword]"

Search

Sponsor content

73 result(s) found, displaying 41 to 50

Allergan Australia Pty Ltd - Balloon, gastric, appetite-suppressing Cancelled under s41GL(d) of the Act

30 June 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
Allergan Australia Pty Ltd - Balloon, gastric, appetite-suppressing Cancelled under s41GL(d) of the Act

30 June 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
LATISSE topical solution (bimatoprost 300 microgram/mL) bottle Cancelled under s30(1)(c)

12 May 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
LATISSE topical solution (bimatoprost 300 microgram/mL) bottle Cancelled under s30(1)(c) of the Act

12 May 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
AusPAR: Deoxycholic acid

6 April 2017

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Deoxycholic acid
LATISSE ophthalmic solution (bimatoprost 0.3 mg/mL) Cancelled under s30(1)(c)

24 April 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
LATISSE topical solution (bimatoprost 300 microgram/mL) Cancelled under s30(1)(c)

24 April 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
LATISSE ophthalmic solution (bimatoprost 0.3 mg/mL) Cancelled under s30(1)(c) of the Act

24 April 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
LATISSE topical solution (bimatoprost 300 microgram/mL) Cancelled under s30(1)(c) of the Act

24 April 2017

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd
ALBALON RELIEF phenylephrine hydrochloride 1.2mg/mL single dose eye drops solution ampoule Cancelled under s30(1)(c)

21 December 2016

Cancellation by sponsor

Requested by Allergan Australia Pty Ltd

Pages

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.